Agoracom Blog Home

Posts Tagged ‘Marijuana’

Mota Ventures $MOTA.ca Reports Monthly Revenues of Cdn$5,141,000 for Natures Exclusive, Highest in the History of the Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:19 AM on Wednesday, June 10th, 2020
  • Revenue for the month of May totaled Cdn$5,141,000, representing an increase of 110% compared to May 2019
  • 23,141 new customers during the month of May 2020

VANCOUVER, BC, CANADA / ACCESSWIRE / June 10, 2020 / Mota Ventures Corp. (CSE:MOTA) (FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) the Company’s subsidiary, Nature’s Exclusive, an eCommerce provider of CBD products to consumers in the United States, is pleased to announce an all-time monthly revenue record achieved during May 2020. Revenue for the month of May totaled Cdn$5,141,000, representing an increase of 110% compared to May 2019. Expenses totaled Cdn$4,992,000 for the month, representing a gross profit of Cdn$149,000 for May 2020.

The Company’s investment in customer acquisition continues to yield benefits with the brand acquiring 23,141 new customers during the month of May 2020. The Company’s strong ability to continue to acquire and retain new customers for its products continues to accelerate. As consumers continue to seek natural health product solutions, the Nature’s Exclusive brand is well positioned to offer consumers quality and convenience.

NATURE’S EXCLUSIVE CBD BRAND LEADING THE WAY

The Company’s Nature’s Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Nature’s Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee.

“I am very pleased our Nature’s Exclusive brand achieved another monthly sales record. We continued to expand in the United States, and our outlook for the second half of fiscal 2020 is very positive. We remain on track to achieve our goals for 2020 despite the recent economic turmoil,” stated Ryan Hoggan, CEO of the Company.

We encourage readers to visit www.motaventuresco.com to view our brands and sign up to our newsletter.

The Company cautions that figures for revenue, expenses and margin generated from the sale of Nature’s Exclusive products in fiscal year 2020 have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.397 for May 2020 and US$1.00:Cdn$1.3459 for May 2019.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In Germany, Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

CLIENT FEATURE: TransCanna Holdings $TCAN.ca Developing the Largest Multi-Purpose #Cannabis Facility in California $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:08 PM on Monday, June 8th, 2020
tcan-square

(CSE: TCAN) (FSE: TH8)

Why TransCanna?

  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

THE FACILITY – 196,000 Sq Ft DALY BUILDING

  • Located in Modesto, California; A key asset for TransCanna
  • 196,000 square foot building has an appraised value, prior to licensing and build out, of US $15m.
  • The indicative value once operational, post-licensing and build out is projected at US $80m.
  • Will be the largest multi-purpose cannabis facility in California.
  • Electricity Rates amongst the lowest in California

FULL DISCLOSURE: TransCanna Holdings is an advertising client of AGORA Internet Relations Corp.

Mota Ventures $MOTA.ca Signs Binding Term Sheet to Acquire E-Commerce Platform Leader Unified Funding with C$93.8 Million in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:32 AM on Saturday, June 6th, 2020

June 6, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce that it has entered into a binding term sheet (the “Term Sheet“) dated June 5, 2020 with Unified Funding LLC (“Unified“). The term sheet replaces the previous preliminary letter of intent entered into with Unified on May 21, 2020.

Ryan Hoggan, Chief Executive Officer stated “The very nature of CBD, natural health products and psychedelics unequivocally points the future of our nascent industry into digital targeting, marketing and engagement of customers who will turn to the web to learn about and acquire the right products for them. Mota has already demonstrated superior eCommerce capabilities in 2020 but this acquisition of Unified will make us a formidable presence in the space.”

Hoggan added “From a shareholder value point of view, the one thing the biggest tech companies in the world have in common – according to McKinsey – is that they are all platform-based organizations that owe much of their success to the agility with which they are able to innovate and reconfigure themselves to go after new opportunities. With this acquisition, we hope to establish a platform that will serve a growing global industry going forward.”

PLATFORM HAS FACILITATED C$364 MILLION IN TRANSACTIONS SINCE 2015, C$93.8 MILLION IN 2019

Unified is a leading eCommerce platform company established in 2015 by partners with over a decade experience in eCommerce marketing. Unified has developed a proprietary technology platform along with a CRM designed specifically for emerging, small and medium sized eCommerce businesses worldwide. To date, the platform has successfully facilitated over CDN$364,000,000 in consumer transactions, including CDN$93,800,000 in 2019 alone.

The platform generates revenue from licensing, marketing and product fulfillment fees supporting brands in the natural health products sector, including skin care, nutraceutical, essential oils and CBD. Unified brings the platform and experience needed for the Company to expand its product portfolio and brands. Integration of the platform with the Unified experienced team of professionals to run it will allow the Company to develop new products and enter new natural healthcare markets, aided significantly by Unified’s ability to closely track current trends through a global network of media partners.

Kevin Keranen, Chairman of Unified, stated “Along with a diverse team of eCommerce experts, we have built one of the most comprehensive eCommerce platforms in the natural health products sector. Our combination of technology with a full team of individuals dedicated to specific segments of the business allows us to deliver robust growth for our clients. As we look to become a part of Mota, we will be able to access the growth capital to further expand our marketing efforts and support any initiative drive by the Company in a more strategic manner.”

UNIFIED PLATFORM GOES BEYOND PRODUCT SALES

Unified provides a comprehensive suite of managed services in high-demand by its clients. These services are driven by both technology and a team of over forty United States based employees that include:

Customer Acquisition: Unified creates and executes digital marketing campaigns to acquire customers in the clients targeted demographic. By utilizing Unified’s vast marketing channels, clients are able to learn about new market trends and adapt accordingly.

Product Development: Unified is able to guide product development by utilizing intelligence generated by the millions of customer records of opt-in buyers and potential buyers. Unified has relationships with product development professionals, labs and manufacturers to create products within scope and within budget.

Supply Chain Management & Logistics: Through its partners, Unified can help manage clients supply chain to ensure on-time delivery to each customer’s doorstep and to adapt to varying levels of product demand.

Customer Service: As part of the technology platform, Unified provides real-time customer service metrics to accurately measure performance of each customer service agent, which significantly impacts the profitability of each clients business.

Profitability Analysis: Most importantly, the technology and staff at Unified are focused on profitability for each and every client. The business manages over 100 key performance indicators that have been developed through experience, which translates to higher success rates for Unified clients.

PROPOSED TRANSACTION

The Letter of Intent contemplates that the Company would acquire Unified in consideration for US$45,000,000, which will be satisfied through the issuance of common shares of the Company (the “Consideration Shares“). The Consideration Shares will be issuable at a deemed price (the “Transaction Price“) equivalent to the greater of: (i) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the entering into of a definitive agreement in respect of the acquisition, and (ii) Cdn$0.40.

In addition to the Consideration Shares, Unified will be entitled to receive a one-time bonus payment of US$15,000,000 (the “Bonus Payment“) in the event the Company achieves gross revenue in excess of US$15,000,000 from the Unified business in the twelve-month period following closing of the acquisition. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“), at the Transaction Price.

The Consideration Shares, and the Bonus Shares, will be subject to terms of a thirty-six month time-release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The shares will be released from the pooling arrangement in tranches, of which twenty percent will be released upon issuance, and the balance in six equal tranches every six months thereafter.

Completion of the proposed acquisition of Unified remains subject to a number of conditions, including, but not limited to, satisfactory completion of due diligence, negotiation of definitive documentation and the receipt of any required regulatory approvals. The acquisition cannot be completed until these conditions are satisfied and there can be no assurance that the acquisition will be completed at all.

The proposed acquisition is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding the proposed acquisition, as that information becomes available.

This press release is available for investor discussion on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada closing exchange rate on June 3, 2020 of US$1.00:Cdn$1.3504.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In German Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Primo Nutraceuticals Inc.,$PRMO.ca and World Agri Minerals Ltd. Discuss Potential Development of a Proprietary Natural Mineral Blend to Increase Production for Mushroom Growers $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 8:24 AM on Friday, June 5th, 2020
  • Announced that further to its letter of intent with World Agri-Minerals Ltd. , announced in the Company’s news release dated June 4, 2020, Primo and WAM have conducted discussions relating to the development and production of a proprietary mineral blend specially designed for employment by psilocybin mushroom growers
  • Company has identified growing global interest in the potential medical applications of psilocybin and other psychedelic mushrooms
  • WAM claims that their current research and testing will result in benefits similar to those attained when using their already successful GENESIS 89 GOLD blend on Hemp and Cannabis production.

VANCOUVER, British Columbia, June 05, 2020 – PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that further to its letter of intent (“LOI”) with World Agri-Minerals Ltd. (“WAM”), announced in the Company’s news release dated June 4, 2020, Primo and WAM have conducted discussions relating to the development and production of a proprietary mineral blend specially designed for employment by psilocybin mushroom growers.

The Company has identified growing global interest in the potential medical applications of psilocybin and other psychedelic mushrooms. With world-wide interest in this burgeoning Agri-landscape, WAM is currently developing a new proprietary mineral blend focused on enhancing the production and quality of mushrooms and in particular psychedelic mushroom production. WAM claims that their current research and testing will result in benefits similar to those attained when using their already successful GENESIS 89 GOLD blend on Hemp and Cannabis production. With the new WAM proprietary mineral natural mushroom blend, a healthy more vibrant and 100% organic product can be grown more economically thereby allowing product cost savings for the consumers in addition to enabling growers to be more efficient and profitable. WAM claims that that GENESIS 89 GOLD can increase Hemp and Cannabis productivity anywhere from 15% to 35%. WAM believes that a new mushroom blend could provide similar if not greater production numbers for psilocybin and other mushroom varieties grown for medical applications.

The Mushroom Market

According to the Psychedelic Science Review, the global market for conventional anti-depressants was valued at $13.7 billion in 2016 and is projected to grow to $15.9 billion by 2023.

Andy Jagpal, President Comments:

“We believe that Primo is especially well positioned to capitalize on the emerging ‘shroom boom’ Psilobycin and other varieties of mushrooms are quickly becoming a viable option for mental and physical health treatment. The market for investment opportunity is massive for a nutraceutical company like Primo which has demonstrated its ability to receive NPNs (Natural Product Number) from the Health Products and Food Branch of Health Canada for nutraceutical products.”

About World Agri Minerals Ltd. (WAM)

WAM was formed to actively pursue the manufacturing, marketing and sales of its premiere commercial Agri-product GENESIS 89, an organic plant nutrient that has a proven positive effect on agri-production. WAM now plans to use this same unique blending process to change the way the mushroom industry grows and fertilizes their product. With over 80 trace minerals, GENESIS 89 and GENESIS 89 GOLD contains a proprietary blend that boasts the highest concentration of seawater-harvested minerals available on the commercial and retail market.

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoid (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected]

To learn more about what this news means to the shareholders visit:

Shop: www.primoceuticals.com

www.twitter.com/prmonutra

https://t.me/PrimoNutraceuticals

www.thrivecbd.org

www.beautykitchen.net

www.drinkdefy.com

www.worldagriminerals.com

Corporate: www.primonutraceuticals.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

VIDEO: Transcanna $TCAN.ca Revenue Run Rate Of $24M Will Increase To $90M When 196,000 Sq Ft Facility Comes Online In 2021

Posted by AGORACOM-JC at 4:04 PM on Wednesday, June 3rd, 2020
tcan-square
  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

Primo Nutraceuticals Inc. $PRMO.ca Signs Letter of Intent to Enter into Funding and Asset Purchase Agreement with World Agri Minerals Ltd. $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 9:13 AM on Wednesday, June 3rd, 2020
  • Announced that it has signed a non-binding letter of intent to provide funding and to acquire up to 100% of the assets and inventory of World Agri Minerals Ltd.
  • WAM is engaged in the research and development of enhanced production methods using organic plant nutrients and trace minerals found in its GENESIS 89 and GENESIS 89 GOLD product line
  • Products are completed and ready for sales and distribution to growers as a concentrate
  • Product interest has been global

VANCOUVER, British Columbia, June 03, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that it has signed a non-binding letter of intent (“LOI”) to provide funding and to acquire up to 100% of the assets and inventory of World Agri Minerals Ltd. (“WAM”), together (the “Parties”). WAM is engaged in the research and development of enhanced production methods using organic plant nutrients and trace minerals found in its GENESIS 89 and GENESIS 89 GOLD product line.

WAM was formed to actively pursue the manufacturing, marketing and sales of its premiere commercial agri-product GENESIS 89, an organic plant nutrient that has a proven positive effect on agri-production. WAM now plans to use this same unique blending process to change the way the mushroom industry grows and fertilizes their product. With over 80 trace minerals, GENESIS 89 contains a proprietary blend that boasts the highest concentration of seawater-harvested minerals available on the commercial and retail market.

Current products “GENESIS 89” and “GENESIS 89 GOLD” are completed and ready for sales and distribution to growers as a concentrate. Product interest has been global. As well, several new products are in the research and development phase, not the least of which is a unique blend of trace minerals, similar to that of GENESIS 89 GOLD, designed specifically for the psychedelic mushroom marketplace. WAM is positioned with upward trending organic agri-farming, as well as the medical and recreational hemp/cannabis and psychedelic mushroom industries.

The Parties intend to draft and execute a definitive agreement (the “Definitive Agreement”) with detailed terms as soon as practicable, and complete the transaction on or before June 20, 2020. Terms of the LOI are subject to change as set out in the Definitive Agreement. The final valuation will be determined by an independent third-party evaluator, which is currently in progress.

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoid (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected]

To learn more about what this news means to the shareholders visit:

Shop: www.primoceuticals.com

www.twitter.com/prmonutra

https://t.me/PrimoNutraceuticals

www.thrivecbd.org

www.beautykitchen.net

www.drinkdefy.com

www.worldagriminerals.com

Corporate: www.primonutraceuticals.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/77b24a04-64f8-4f81-93b8-737e3a6dbc82

agri-product GENESIS 89
an organic plant nutrient that has a proven positive effect on agri-production

Source: GlobeNewswire (June 3, 2020 – 9:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

TransCanna $TCAN.ca and KeyPLex Collobrate on Innovative Suite of Agro Products to Boost Yield, Treat Plant Pests and Disease $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:14 AM on Wednesday, June 3rd, 2020
tcan-square
  • Entered into a Memorandum of Understanding with major agriculture firm KeyPlex, to create and market high quality bio-pesticides, bio-fungicides, and fertilizers with micronutrients specifically created for the cannabis industry
  • Marks the first time a line of bio-controls and specifically formulated fertilizers designed to increase plant vigor during each stage of the life cycle, will be created for the unique needs of cannabis and hemp crops.

Vancouver, British Columbia–(June 3, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with major agriculture firm KeyPlex, to create and market high quality bio-pesticides, bio-fungicides, and fertilizers with micronutrients specifically created for the cannabis industry.

The MOU between the global agricultural powerhouse and Lyfted Farms (a TransCanna subsidiary) marks the first time a line of bio-controls and specifically formulated fertilizers designed to increase plant vigor during each stage of the life cycle, will be created for the unique needs of cannabis and hemp crops. In addition, the all-natural, product lines co-branded by the companies meet the standards required to pass stringent testing in order to be compliant in the highly competitive California cannabis space.

Improving soil and plant health via comprehensive nutritional inputs and biostimulants that make nutrient uptake more effective for cannabis plants has several benefits, including increased yields and disease resistance, and improved pest resistance, which can lead to higher profit margins. In addition, healthier soil requires less water, leading to more sustainable water use and lowered associated costs.

“No one has ever created a similar product range targeting the unique needs of cannabis growers before, so we are pleased to offer a portfolio that will benefit growers and sustainable growing practices in addition to cannabis consumers via high quality and all-natural products,” says Bob Blink, TransCanna CEO. “We are pleased to be working with one of the most respected and largest agriculture brands sharing the same values that we do for sustainable agriculture practices to promote the progressiveness and longevity of our industry.”

“This partnership with KeyPlex,” adds Blink, “to offer cutting edge technology reflects our overall strategy to be innovators in the Cannabis space and to live up to the Lyfted Farms motto of ‘a higher standard of growing.'”

In addition, the products offered through this have no pre-harvest interval, zero worker re-entry restrictions, and have no residual testing limitations.

KeyPlex is a recognized giant in the agriculture industry and global market leader in plant pest and disease control and nutrient input programs. The company was established in 1980 and specializes in sustainable, environmentally friendly, botanically based products that are OMRI certified, EPA exempt, and approved for use in California on all cannabis and hemp varieties. KeyPlex products are currently sold across North America, South America and Europe.

“Lyfted Farms was selected to be our sole partner in this exciting new venture because of its reputation for cultivation expertise and the noted quality of its cannabis flower,” said Gerald O’Connor, CEO of KeyPlex. “We share a passion for innovating and for pushing the standards of quality to meet the needs of producers and with end user safety in mind.”

The first two product offerings are in final-phase development and include a broad-spectrum fungicide and a plant-based insecticide that have demonstrated remarkable effectiveness in repeated crop cycles conducted at Lyfted Farms test facility sites in Modesto, CA.

For more information on this MOU and other TransCanna news please visit us our Agoracom investor community:

https://agoracom.com/ir/TranscannaHoldings/forums/discussion/topics/741323-interview-will-be-live-on-wednesday-june-2nd-at-4pm-est/messages/2268937#message

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primo Nutraceuticals Inc. $PRMO.ca Receives Approval to Sell its Hand Sanitizer on #Amazon.com $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 9:20 AM on Tuesday, June 2nd, 2020
  • Announced that it has received approval from Amazon to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category
  • Through continued perseverance and multiple discussions with customer care, and due to Primo meeting all the required criteria as a licensed establishment with a product that has been licensed and approved by Health Canada, Primo was finally granted permission from Amazon to sell its hand sanitizer on their website.

VANCOUVER, British Columbia, June 02, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that it has received approval from Amazon to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category.

In response to the increasing demand for hand sanitizers in Canada, approximately two months ago Primo filled out an online application to sell its hand sanitizer on Amazon. Primo was granted a Seller Central account but was initially denied the ability to list its hand sanitizer, as Amazon was no longer approving new listings in this category. In early March, Amazon began restricting the types of sellers on its third-party Marketplace platform that are able to sell health and sanitation products, such as: face masks, hand sanitizer, disinfecting wipes/ sprays, isopropyl alcohol, among other products. 

Through continued perseverance and multiple discussions with customer care, and due to Primo meeting all the required criteria as a licensed establishment with a product that has been licensed and approved by Health Canada, Primo was finally granted permission from Amazon to sell its hand sanitizer on their website.

The approval by Amazon could not have come at a better time for the company as its first shipment of hand sanitizer was picked up at their manufacturer on Friday, May 29th, 2020 with an expected delivery of later this week.

In reference to the company’s press release dated March 24th, Primo will be handing out the hand sanitizer as well as promotional samples for procurement departments in the healthcare industry across Canada to essential workers.

The company will also be taking the opportunity to hand out samples to potential customers that are interested in purchasing the hand sanitizer in bulk orders.

To view the product brochure, please visit: https://www.primoceuticals.com/shop#!/Primo-Lemon-Hand-Sanitizer-60/p/197662415/category=0

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC. 

“Andy Jagpal” 

President and Director 

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] 

To learn more about what this news means to the shareholders visit: 

Shop: www.primoceuticals.com 

www.twitter.com/prmonutra 

https://t.me/PrimoNutraceuticals

www.thrivecbd.org 

www.beautykitchen.net 

www.drinkdefy.com 

Corporate: www.primonutraceuticals.com 

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Mota Ventures $MOTA.ca Closes $20,000,000 Acquisition of European Pharmaceutical Manufacturer of Natural Psilocybin Extracts $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:41 AM on Tuesday, June 2nd, 2020
  • The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion

VANCOUVER, BC / June 2, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) a leading ecommerce provider of CBD products to consumers in the United States and Europe, is pleased to announce the completion of its’ Cdn$20,000,000 acquisition (the “Transaction“) of all of the outstanding share capital of Verrian Ontario Ltd. (“Verrian“) effective June 1, 2020. Verrian is an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

Ryan Hoggan, CEO of the Company stated, “The massive shift towards psychedelic derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade. Unlike some companies that use psychedelics as a marketing term, this acquisition of Verrian brings Mota market ready products, world renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion this is the most complete psychedelic asset on the market, and therefore should immediately make Mota a market leader in the space.”

Hoggan further added, “In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CBD sales. We intend to bring that same market expertise to bear with our psychedelics business in 2020 and far beyond.”

ACQUISTION PROVIDES MOTA WITH IMMEDIATE ENTRY INTO FAST GROWING $100 BILLION PSYCHEDELICS INDUSTRY

The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion*. Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.

As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.

Verrian has already developed two psilocybin products that are natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs. This is only the beginning with further products in various stages of development.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Verrian operates three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

In consideration for the acquisition of all of the outstanding share capital of Verrian, the Company has issued 54,347,826 common shares (the “Consideration Shares“) to the existing shareholders of Verrian at a deemed price of $0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company has arranged for repayment of $150,000 of existing shareholder loans of Verrian, and will arrange for repayment of the balance of $950,000 within sixty days of closing.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Company has paid a finders’ fee of 5,434,783 common shares to certain arms’-length parties who have assisted in facilitating the Transaction. The Company has also paid an administrative fee of 1,086,957 common shares of the Company to a consultant who assisted with the Transaction.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through its powerful eCommerce business, Mota is a leading is a direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the United States through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.

Through its German-based Verrian operation, Mota is researching and testing the efficacy and application of natural psilocybin products for the treatment of opioid and other life altering addictions. Mota is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD and other natural health products.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

AGORACOM Welcomes TransCanna $TCAN.ca Developing The largest Multi-Purpose #Cannabis Facility in California, $2M In April Revenues and $24.6M Run Rate From Test Facility $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 2:23 PM on Friday, May 29th, 2020
TransCanna (@TransCanna) | Twitter

(CSE: TCAN) (FSE: TH8)

Why TransCanna?

  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

THE FACILITY – 196,000 Sq Ft DALY BUILDING

  • Located in Modesto, California; A key asset for TransCanna
  • 196,000 square foot building has an appraised value, prior to licensing and build out, of US $15m.
  • The indicative value once operational, post-licensing and build out is projected at US $80m.
  • Will be the largest multi-purpose cannabis facility in California.
  • Electricity Rates amongst the lowest in California

Daly building will serve as TransCanna’s operations headquarters and will house manufacturing, distribution and cultivation space.

A breakdown of the 196,000 square feet upon completion will be:

  • 45,000 square feet of manufacturing
  • 50,000 square feet of distribution, packaging and cannabis storage
  • 60,000 square feet of indoor cultivation space
  • 5,000 square feet of independent lab for product testing
  • 36,000 square feet of offices, equipment maintenance, employee areas
https://youtu.be/CbZz_yZQ4nE